SCCA expression correlates to high grade breast cancer in the CDP progression TMA.

<p>The three CDP progression TMA case sets (designated as Case Sets 3, 5, and 7 by CDP) were probed for SCCA expression and scored. The grading information was provided by CDP in 291 accountable samples.</p

SCCA expression correlates to a decreased overall survival and recurrence-free survival.

<p>IHC was performed using the SCCA antibody FL-390 on the CDP prognostic TMAs. Kaplan-Meier survival curves for all patients (A–B) and only Grade II and Grade III patients (C–D) with SCCA-positive and negative tumors were compared for overall survival (A&C) and recurrence-free survival (B&D).</p

SCCA expression correlates to high grade breast carcinomas.

<p>The cumulative results of the SCCA positivity against the breast carcinoma grading from the CDP progression and prognostic TMAs are shown. SCCA is negative in the 124 normal or non-neoplastic cases of breast tissue. SCCA is positive in 1 of the 330 (0.3%) Grade I cases, 16 of the 638 (2.5%) Grade II cases, and in 37 of the 392 (9.4%) Grade III cases.</p

Validation of SCCA antibodies.

<p>293T cells were transfected with either vector alone, Flag-SCCA1, or Flag-SCCA2 plasmids. (A) Cells were subjected to immunoblot analysis using three SCCA antibodies: FL-390 for SCCA1/2, 8H11 for SCCA1, and 10C12 for SCCA2, as well as Flag antibody and β-tubulin antibody. (B) Cells were fixed and embedded in paraffin. IHC was performed with FL-390 and 10C12 antibodies. (C) IHC was performed on normal human tissue using the antibody Clone FL-390. Scale bars  = 50 µm.</p

Elevated SCCA expression is found in human breast cancer cell lines and human breast cancer carcinomas, but not in normal breast epithelium.

<p>(A) A panel of human cancer cells was probed for SCCA expression by immunoblotting. Five out of the six breast cancer cell lines (denoted with an asterisk) were positive for SCCA expression. (B) IHC analysis was performed on an array of breast carcinomas and normal breast tissue obtained from CHTN, using antibody FL-390. Representative images of normal breast tissue and sections with Grade III invasive ductal carcinoma are shown. (C) IHC staining was performed on the NCI CDP breast cancer progression and the prognostic TMAs using antibody FL-390. SCCA staining was scored on a tiered-scale (0–3). A representative panel is shown. Scale bars  = 50 µm.</p

SCCA expression correlates to advanced stage breast carcinomas.

<p>The Stage I, Stage II, and Stage III prognostic TMAs were obtained from CDP. IHC was against SCCA. The tissue was scored and the SCCA-positive cases are shown in parentheses against the number of cases for each stage. Note that all of the normal tissue were SCCA-negative, whereas 14 out of 573 (2.4%) Stage I, 12 out of the 391 (3.1%) Stage II, and 15 out of 174 (8.6%) Stage III cases were SCCA-positive.</p

SCCA expression correlates to high grade breast carcinoma in the CDP prognostic TMA.

<p>The Stage I (Case Sets 9–13), Stage II (Case Sets 14–17), and Stage III (Case Sets 18–19) prognostic TMAs were obtained from CDP, containing 598, 411, and 184 tissue specimens, respectively. IHC was performed against SCCA. The tissue was scored and the SCCA-positive cases are shown in parentheses against the number of cases in each grade. Note that all of the normal tissue were SCCA-negative, whereas 1 out of 294 Grade I, 11 out of the 534 Grade II, and 29 out of 310 Grade III cases were SCCA-positive.</p